Active Clinical Trials at OOS
All Clinical Trials
AbbVie (M23-362)
Tumor site:
Hematologic (MDS, CMML, AML)
Description:
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting
Available at:
Notes:
Sponsor: AbbVie; NCT Number: NCT05451810
ASTX030-01
Tumor site:
Hematologic (MDS, CMML, AML)
Description:
**Enrollment on Hold** A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Available at:
More info:
Notes:
Sponsor: Astex; NCT Number: NCT04256317
Amplitude (67652000PCR3002)
Tumor site:
Prostate
Description:
***Enrollment closed*** A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Available at:
More info:
Notes:
Sponsor: Janssen; NCT Number: NCT04497844
B Stronger I (01-PS-001)
Tumor site:
Breast
Description:
Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
Available at:
More info:
Notes:
Sponsor: Personalis; NCT Number: NCT06230185
AVANZAR (D926NC00001)
Tumor site:
Lung
Description:
**Enrollment Closed** A Phase III, Randomized, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Available at:
More info:
Notes:
Sponsor: AstraZeneca; NCT Number: NCT05687266
BDX-00146
Tumor site:
Lung
Description:
**Enrollment Closed** An Observational Study Assessing the Clinical Effectiveness of the VeriStrat® Test and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer (INSIGHT)
Available at:
More info:
Notes:
Sponsor: Biodesix Inc; NCT Number: NCT03289780
BillionToOne (NS-001)
Tumor site:
Solid Tumors
Description:
Compare the clinical relevant biomarkers identified by a novel BillionToOne quantitative ctDNA somatic mutation profiling assay with clinically available comparable assays in patients with advanced stage solid tumors.
Available at:
Notes:
Study Sponsor: BillionToOne Inc.; IRB number: 20230250
BillionToOne (NS-002)
Tumor site:
Solid Tumors
Description:
Tumor methylation scores will be quantified at baseline across all tumor types to establish the clinical limit of detection of the assay. Associations between baseline tumor methylation score and PFS, OS, and disease control rate will be examined across therapeutic regimens and cancer types to test the hypothesis that the TMS is prognostic of outcome.
Available at:
Notes:
Study Sponsor: BillionToOne Inc.; IRB number: 20231272
Furmo (Furmo-004)
Tumor site:
Lung
Description:
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Available at:
Notes:
Sponsor:ArriVent BioPharma, Inc.; NCT Number: 05607550
G000 (BB-1701-G000-205)
Tumor site:
Breast
Description:
**Enrollment on Hold** An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Available at:
Notes:
Sponsor: Eisai Inc.; NCT Number: NCT06188559
GEMINI
Tumor site:
Lung
Description:
TEMPUS GEMINI (TP-CA-002) NSCLC SURVEILLANCE STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC)
Available at:
More info:
Notes:
Sponsor: Tempus; IRB Number: NCT05236114
INTRINSIC
Tumor site:
Colorectal Cancer
Description:
**Enrollment on Hold** A Phase I/Ib global, multicenter, open-label umbrella study evaluating the safety and efficacy of targeted therapies in subpopulations of patients with metastatic colorectal cancer
Available at:
More info:
Notes:
Sponsor: Roche; NCT Number: NCT04929223
Mirati KRYSTAL 7
Tumor site:
Lung (NSCLC)
Description:
Phase 3 Trial of MRTX849 Plus Pembrolizumab for NSCLC With KRAS G12C Mutation (KRYSTAL-7)
Available at:
More info:
Notes:
Sponsor: Mirati Therapeutics Inc; NCT Numer: NCT04613596
Ovation-23-001
Tumor site:
Breast; Lung
Description:
Collection of Biological Specimens and Associated Health Information for Secondary Research in Future Studies
Available at:
More info:
Notes:
Ovation.io, Inc. NCT# NCT06369441
VIKTORIA-1
Tumor site:
Breast
Description:
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Available at:
More info:
Notes:
Sponsor: Celcuity; NCT Number: NCT05501886
Page 1 of
Page: